


Substitute for form 1449A/PTO  
**INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT**  
 (Use as many sheets as necessary)



PTO/SB/08A(10-01)  
 Approved for use through 10/31/2002, OMB 051-0031  
 US Patent & Trademark Office, U.S. DEPARTMENT OF COMMERCE  
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known	
Application Number	10/032,376
Filing Date	December 21, 2001
First Named Inventor	Quirk, Stephen
Group Art Unit	1654
Examiner Name	Audet, Maury
Attorney Docket No: 1443.008US1	

Sheet 1 of 2

### US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate
	US-2003/0012794A1	01/16/2003	Srivastava, P. K., et al.	08/02/2002
	US-2004/0010001A1	01/15/2004	Au, J. L., et al.	06/18/2003
	US-6,482,802	11/19/2002	Hu, G.-F., et al.	11/09/2000
	US-6,906,036	06/14/2005	Quirk, S., et al.	05/21/2002

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T <sup>2</sup>
	WO-0074634A2	12/14/2000	Au, J. L., et al.	
	WO-03018748A2	03/06/2003	Quirk, S., et al.	
	WO-9834641A1	08/13/1998	Srivastava, P. K., et al.	
	WO-9958126A1	11/18/1999	Hu, G.-F., et al.	

### OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		COPPOLA, G., et al., "Effect of Intraperitoneally, Intravenously and Intralesionally Administered Monoclonal Anti-Beta-FGF Antibodies on Rat Chondrosarcoma Tumour Vascularization and Growth", <u>Anticancer Research</u> , 17(3C), (1997),2033-2040	
		DAILEY, L., et al., "A Network of Transcriptional and Signaling Events is Activated by FGF to Induce Chondrocyte Growth Arrest and Differentiation", <u>The Journal of Cell Biology</u> , 161(6), (2003),1053-1066	
		FUJISAWA, N., et al., "Inhibitory Effects of Transforming Growth Factor - Beta1 Pretreatment on Experimental Pulmonary Metastasis of MCS-1 Chinese Hamster Mesenchymal Chondrosarcoma Cells", <u>Tohoku J. Exp. Med.</u> , 187, (1999),203-213	
		GIGANT-HUSELSTEIN, C., et al., "In vitro Study of Intracellular IL-1 Beta Production and Beta 1 Integrins Expression in Stimulated Chondrocytes - Effect of Rhein", <u>Biorheology</u> , 39(1, 2), (2002),277-285	

EXAMINER

DATE CONSIDERED

10/06


Substitute Disclosure Statement Form (PTO-1449)  
 \* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Application Number	10/032,376
Filing Date	December 21, 2001
First Named Inventor	Quirk, Stephen
Group Art Unit	1654
Examiner Name	Audet, Maury

Sheet 2 of 2

Attorney Docket No: 1443.008US1

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		KEARNS, A. E., "Initiation of Chondroitin Sulfate Biosynthesis: A Kinetic Analysis of UDP-d-Xylose: Core Protein Beta-D-Xylosyltransferase", <u>Biochemistry</u> , 30(30), (1991),7477-7483	
		LIACINI, A. , et al., "Induction of Matrix Metalloproteinase-13 Gene Expression by TNF-alpha is Mediated by MAP Kinases, AP-1, and NF-kB Transcription Factors in Articular Chondrocytes", <u>Experimental Cell Research</u> , 288(1), (2003),208-217	
		RAUCCI, A. , et al., "Activation of the ERK1/2 and p38 Mitogen-Activated Protein Kinase Pathways Mediates Fibroblast Growth Factor-Induced Growth Arrest of Chondrocytes", <u>The Journal of Biological Chemistry</u> , 279(3), (2004),1747-1756	
		RODRIGUEZ-MANZANEQUE, J. C. , et al., "ADAMTS1 Cleaves Aggrecan at Multiple Sites and is Differentially Inhibited by Metalloproteinase Inhibitors", <u>Biochemical and Biophysical Research Communications</u> , 293(1), (2002),501-508	
		SAHNI, M. , et al., "FGF Signaling Inhibits Chondrocyte Proliferation and Regulates Bone Development Through the STAT-1 Pathway", <u>Genes &amp; Development</u> , 13(11), (1999),1361-1366	
		SEONG, S.-C. , et al., "Insulin-Like Growth Factor I Regulation of Swarm Rat Chondrosarcoma Chondrocytes in Culture", <u>Experimental Cell Research</u> , 211, (1994),238-244	
		WU, C. , et al., "Furin-Mediated Processing of Pro-C-Type Natriuretic Peptide", <u>The Journal of Biological Chemistry</u> , 278(28), (2003),25847-25852	

EXAMINER

DATE CONSIDERED

10/06

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) ; Applicant is to place a check mark here if English language Translation is attached